NasdaqCM:ONCYBiotechs
Why Oncolytics Biotech (ONCY) Is Up 14.5% After New Pelareorep RAS-Tumor Immune Activation Data
In late May and early June 2026, Oncolytics Biotech reported new preclinical and translational data showing pelareorep’s enhanced anti-tumor activity and multi-step immune activation in difficult-to-treat, RAS-driven solid tumors, including pancreatic and breast cancer.
The findings highlight pelareorep’s potential to expand virus- and tumor-specific T cells, engage KRAS-targeted immune responses, and support combinations with next-generation RAS inhibitors.
With recent results...